FDA Grants Accelerated Approval to Zenocutuzumab-zbco for Non-Small Cell Lung Cancer and Pancreatic Adenocarcinoma By Ogkologos - January 10, 2025 837 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the eNRGy study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Joins WHO Global Clinical Trials Forum to Strengthen Global Oncology Research Ecosystems EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis MOST POPULAR Science Surgery: ‘Can cancers develop in the heart?’ March 30, 2021 EMA Recommends Extension of Indications for Trastuzumab Deruxtecan July 21, 2022 New Risk Model Aims to Reduce Breast Cancer Disparities in Black... December 6, 2021 Prising open the trap: Getting to grips with targeted cancer drug... January 10, 2022 Load more HOT NEWS Should People with Cancer and Cancer Survivors Get the Flu Vaccine? High-Fat Diet or Diabetes Drug May Enhance Response to Targeted Cancer... FDA Grants Regular Approval to Dostarlimab-gxly for dMMR Endometrial Cancer When Prenatal DNA Tests Point to Cancer
